Consider whether symptoms might indicate: Underlying conditions being unmasked or worsening Effects of other supplements or medications Lifestyle factors like inadequate sleep, poor nutrition, or excessive stress Infections or illnesses unrelated to peptide use If symptoms do not match the expected AOD 9604 profile, persist after discontinuation, or are accompanied by other concerning signs, investigate independently rather than assuming the peptide is responsible
It identifies the subset of patients who truly benefit from supplementation
A lifeline These clinics and technicians provide an essential lifeline for so many who are dragging themselves around trying to survive on one injection every three months whilst trying to function, keep their mental health on track, look after a family, hold down a job and who may have had to home school on top of everything else during this years lockdowns
Severe GI Disease: MOUNJARO has not been studied in severe gastroparesis
Clinical trials involving approximately 900 participants showed that AOD-9604 had no effect on IGF-1 levels and no negative effects on carbohydrate metabolism
Fat loss stacking protocols Several stacking approaches have emerged in clinical practice
